Pfizer and Bristol Myers Squibb both bank on 2028, but investors are weighing different pipeline bets

Pfizer and Bristol-Myers Squibb are being judged through the same lens, even though their drug portfolios are not identical. Both companies are trying to replace revenue from older medicines as they approach the end of market exclusivity, a point when competitors can begin offering cheaper generics or biosimilars and prices typically fall. In that context, an investor debate has resurfaced: what does Bristol-Myers Squibb have that Pfizer does not, and vice versa, as both point to 2028 as a pivotal year for what comes next.

The comparison being discussed frames the core business challenge for each company. Drugmakers that depend heavily on a limited number of big-selling products face a narrowing time window to bring forward new approvals and establish new revenue streams before exclusivity ends. The underlying question is not only which pipeline assets exist, but how soon they can become meaningful commercially, and whether those assets are concentrated enough to offset declines from aging franchises.

According to the market-focused discussion, both companies are effectively building toward the same milestone, 2028. That year matters because it is viewed as a natural inflection point for the next wave of launches and the degree to which the companies can reduce the revenue gap left by products that are losing exclusivity. In other words, the debate is less about near-term expectations and more about whether each firm’s forward pipeline is robust enough to carry the business after major patent-driven pressure begins.

At a high level, the question “what does Bristol-Myers Squibb offer that Pfizer does not” is meant to tease out portfolio differences. Bristol-Myers Squibb and Pfizer do not compete only with each other; they also compete with the broader market’s pace of innovation. Still, for investors comparing two large peers, the most actionable comparison tends to be the mix of late-stage assets, the number of bets that could mature around the same time window, and how effectively those bets map to disease areas where demand is expected to persist.

The market discussion also implies a practical investor concern: companies may be on the same calendar, but not on the same trajectory. Even when two firms highlight the same target year, their pipelines can differ in depth and in the kinds of therapeutic areas they are leaning into. One company may have a higher concentration of potential growth from a smaller set of programs, while another may spread risk across a wider set of candidates.

For Pfizer specifically, the question is implicitly about whether its pipeline and development pipeline timing can match what investors see in Bristol-Myers Squibb’s opportunity set heading into the later part of the decade. For Bristol-Myers Squibb, the inverse question is whether its positioning around 2028 is a stronger insurance policy against exclusivity erosion than what Pfizer can currently claim.

What remains unclear from the information provided for this write-up is which exact Bristol-Myers Squibb programs or therapeutic categories the comparison is using to argue that it has an advantage. The supplied material emphasizes the common “replace exclusivity” problem and the shared importance of 2028, but does not provide enough detail to identify specific drugs, trial milestones, approval timelines, or expected peak-sales implications. As a result, any deeper claim about the specific portfolio gap between the two firms would be speculative in this context.

Investors and industry watchers are likely to focus next on how each company’s mid- to late-stage pipeline progresses toward that 2028 window. The most relevant developments will be advances that reduce uncertainty around timing, including trial readouts, regulatory submissions, and early commercialization indicates when available. Until more program-level detail is confirmed publicly, the debate will remain framed around positioning and pipeline mix rather than fully documented revenue replacement plans.